Support and savings

Support available for your patients

ITF Pharma is committed to being a leader in the amyotrophic lateral sclerosis (ALS) community

  • Dedicated to offering ongoing support and services through every stage of ALS
  • Affiliated with prominent ALS communities that are joining forces to advance survival in ALS through greater knowledge and action
  • Connecting patients and caregivers with empowering ALS advocacy groups and communities

TIGLUTIK co-pay support

  • ITF Pharma offers a co-pay support program to help ensure that people living with ALS, with commercial insurance, get access to TIGLUTIK when they need it
  • TIGLUTIK co-pay support helps reduce out-of-pocket expenses and reduces the financial burden of living with a chronic and rare disease
  • Eligible patients will pay as little as $50 per filled prescription of TIGLUTIK

ELIGIBILITY AND RESTRICTIONS
Offer is valid for each prescription fill for commercially insured patients where TIGLUTIK is covered. Offer is valid for patients age 18 and older. Medicare, Medicaid, TRICARE, or other patients of other federal or state programs are not eligible. ITF Pharma reserves the right to rescind, revoke, or amend this offer without notice. Offer good only in the USA, including Puerto Rico, at participating retail pharmacies. Void if prohibited by law, taxed, or restricted. This offer has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified product. Maximum savings limit applies; patient out-of-pocket expense may vary.

TIGLUTIK is exclusively available through Foundation Care.

Foundation Care streamlines prescribing, simplifying the process of starting patients on a new treatment and offering your patients timely, accurate, and convenient medication delivery.

To fill a prescription, you can easily submit all the required patient information to Foundation Care by:

Phone (toll-free) 855-231-9522

Fax (toll free) 844-572-0969

E-scribe

Mail

Hand delivery

  • Foundation Care will follow up with your office if any required information is missing
  • Foundation Care will contact the patient and/or caregiver within 24 business hours of receiving a prescription
  • The patient and/or caregiver must speak with a Foundation Care representative to complete their order

To ensure a timely and accurate shipment, be sure to:

  • Include “LLC” when searching for the Foundation Care pharmacy
  • Select retail pharmacy instead of specialty pharmacy in your search
  • Remember the Foundation Care NABP/NCPDP Provider ID: 2635564

For more information, contact Foundation Care at 855-231-9522 or www.foundcare.com.

Connecting patients living with ALS and their caregivers

Helping your patients and those who care for them connect with others in similar situations can provide emotional support that can be motivating and inspiring. Remind them that there are local, national, and online communities that can be helpful along their journey with ALS.

ALS Support and Help Forum

A volunteer-driven online support community whose members are ready to share their experiences to help better deal with ALS

Learn more

ALS Association

A nationwide network of local chapters and partners who provide patient and family support in communities across the country

Learn more

EXPAND

Indication and Important Safety Information

Indication

TIGLUTIK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Important Safety Information

Contraindication

TIGLUTIK is contraindicated in patients with a history of severe hypersensitivity reactions to riluzole or to any of its components.

Warnings and Precautions

TIGLUTIK can cause liver injury and there have been cases of drug-induced liver injury, some of which were fatal, in patients taking riluzole. Asymptomatic elevations of hepatic transaminases have been reported and, in some patients, have recurred upon re-challenge with riluzole. Maximum increases in ALT occurred within 3 months after starting riluzole. Monitor patients for hepatic injury every month for the first 3 months of treatment, and periodically thereafter; TIGLUTIK should be discontinued if there is evidence of liver dysfunction, for example, elevated bilirubin. Use of TIGLUTIK with other hepatotoxic drugs may increase the risk for hepatotoxicity.

TIGLUTIK can cause neutropenia. Cases of severe neutropenia (absolute neutrophil count less than 500 per mm3) within the first 2 months of riluzole treatment have been reported. Advise patients to report febrile illnesses.

TIGLUTIK can cause interstitial lung disease, including hypersensitivity pneumonitis. Discontinue TIGLUTIK immediately if interstitial lung disease develops.

Adverse Reactions

The most common adverse reactions (incidence greater than or equal to 5% and greater than placebo) of TIGLUTIK were oral hypoesthesia (29%), asthenia (19%), nausea (16%), decreased lung function (10%), hypertension (5%), and abdominal pain (5%).

Coadministration of TIGLUTIK with strong or moderate CYP1A2 inhibitors, such as ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, and zileuton, may increase the risk of TIGLUTIK-associated adverse reactions.

Coadministration of TIGLUTIK with CYP1A2 inhibitors may result in decreased efficacy of TIGLUTIK.

Use in Specific Populations

Patients with mild or moderate hepatic impairment (Child-Pugh’s score A or B) had increases in AUC compared to patients with normal hepatic function. Thus, patients with mild or moderate hepatic impairment may be at increased risk of adverse reactions. Use of TIGLUTIK is not recommended in patients with baseline elevations of serum aminotransferases greater than 5 times the upper limit of normal or evidence of liver dysfunction.

Japanese patients are more likely to have higher riluzole concentrations, and thus may be at a greater risk of adverse reactions.

Please click here for the Full Prescribing Information.